Publications

The federal 340B Drug Pricing Program allows safety-net providers to buy outpatient drugs at reduced prices and reinvest the savings to serve low-income and uninsured patients. In Michigan, hospitals, clinics, and community health centers use these funds to sustain vital services—from behavioral health and maternity care to discounted prescriptions. While widely used, the program continues to draw debate around transparency, rising drug prices, and market consolidation.

Key Findings

1. Program purpose and scope
Created in 1992, the 340B program helps providers “stretch scarce federal resources” after earlier Medicaid reforms limited access to discounted drugs. Overseen by the Health Resources and Services Administration (HRSA), it now includes 16 classes of healthcare organizations such as hospitals, federally qualified health centers, and Ryan White clinics.

2. Michigan’s participation
Nearly every Michigan legislative district includes 340B-covered providers. Urban hospitals often use savings for free or discounted drugs and patient outreach, while rural hospitals sustain high-cost services like inpatient psychiatry and obstetrics. Smaller clinics rely on the program to maintain primary care and serve uninsured patients.

3. Transparency
Critics say there’s not enough clarity about how hospitals spend 340B savings and note that free-care spending hasn’t always risen. Proponents respond that hospitals undergo regular audits, meet federal reporting standards, and often publish community benefit reports through national associations.

4. Drug costs
Some researchers link 340B discounts to higher drug list prices, but findings are mixed. Supporters argue that manufacturers—not hospitals—set prices and that 340B mitigates the burden of high drug costs for safety-net systems.

5. Market consolidation
Opponents believe 340B encourages hospitals to acquire outpatient practices for financial gain. Others point to broader market pressures—like insurer negotiations and administrative demands—as the main drivers of consolidation.

6. Legislative activity
Federally, new bills like the 340B Transparency Act and PROTECT 340B Act aim to improve oversight and accountability. In Michigan, proposed Senate Bills 94 and 95 would require covered entities to verify compliance, report audit results, and describe community impacts—aligning with similar reforms adopted in other states.

The 340B drug pricing program remains essential to Michigan’s safety-net healthcare system, supporting access for vulnerable populations while sparking ongoing discussions about transparency and accountability. Michigan’s proposed legislation seeks to strengthen reporting requirements without changing the program’s federal framework.

Read the full brief here.